Search results
Showing 331 to 345 of 1254 results for criteria
Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
Evidence-based recommendations on atezolizumab (Tecentriq) for locally advanced or metastatic non-small-cell lung cancer after chemotherapy in adults.
Burosumab for treating X-linked hypophosphataemia in adults (TA993)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.
Bevacizumab gamma for treating wet age-related macular degeneration (TA1022)
Evidence-based recommendations on bevacizumab gamma (Lytenava) for treating wet age-related macular degeneration in adults.
Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)-positive, unresectable, locally advanced or metastatic breast cancer in adults who have had trastuzumab and a taxane.
Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)
Evidence-based recommendations on upadacitinib (Rinvoq) for treating active non-radiographic axial spondyloarthritis in adults.
Our centralised approach to prioritising our guidance topics ensures that we produce guidance that's relevant, timely, accessible, and has demonstrable impact.
Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer in adults.
Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.
Brain tumours (primary) and brain metastases in over 16s (QS203)
This quality standard covers diagnosing, monitoring and managing any type of primary brain tumour or brain metastases in adults (aged 16 or over). It describes high-quality care in priority areas for improvement.
View quality statements for QS203Show all sections
Sections for QS203
- Quality statements
- Quality statement 1: GP direct access to MRI
- Quality statement 2: Named healthcare professional
- Quality statement 3: 5-aminolevulinic acid-guided resection
- Quality statement 4: Risk of late effects of treatment
- Quality statement 5: Neurological rehabilitation
- About this quality standard
NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional
This indicator covers the percentage of diagnoses of sore throat in the preceding 12 months with a recorded FeverPain or Centor score. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes
In development Reference number: GID-TA11559 Expected publication date: 04 September 2026
NICE has reviewed the UK Achondroplasia Network’s consensus guideline for multidisciplinary care of children and young people with achondroplasia
NHS OpenAthens eligibility covers a wide range of those working in health and care, including all staff employed by NHS Trusts. Resources are for users in England only.